Literature DB >> 23943026

Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.

Se Hyun Kim1, Sang Joon Shin, Kang Young Lee, Hyunki Kim, Tae Il Kim, Dae Ryong Kang, Hyuk Hur, Byung So Min, Nam Kyu Kim, Hyun Chul Chung, Jae Kyung Roh, Joong Bae Ahn.   

Abstract

BACKGROUND: The close association between mucinous histology and microsatellite instability (MSI) may have hindered the evaluation of prognostic significance of mucinous histology. The aim of this retrospective study was to investigate whether mucinous histology was associated with a worse prognosis, independent of MSI status, compared to nonmucinous histology in patients with stage III colon cancer.
METHODS: This study enrolled 394 consecutive patients with stage III colorectal cancer treated with adjuvant FOLFOX after curative resection (R0). Clinicopathological information was retrospectively reviewed. Tumors were analyzed for MSI by polymerase chain reaction to determine MSI status. Kaplan-Meier method, log-rank test, and Cox proportional hazard regression models were used.
RESULTS: The estimated rate of 3-year disease-free survival (DFS) in patients with nonmucinous adenocarcinoma (NMA 79.2 %) was significantly greater than that in patients with mucinous adenocarcinoma (MA) and adenocarcinoma with mucinous component (MC) (56.9 %; log-rank, P = 0.002). In univariate analysis, histology (NMA vs. MA/MC), American Joint Committee on Cancer stage (IIIA, IIIB, and IIIC), and lymphovascular invasion (present vs. absent) were significantly associated with DFS. In multivariate analysis, mucinous histology (MA/MC) was associated with decreased DFS in all patients (hazard ratio 1.82, 95 % confidence interval 1.03-3.23, P = 0.0403). In patients with MA/MC, no difference in DFS was observed between MSI and microsatellite stability (log-rank, P = 0.732).
CONCLUSIONS: Mucinous histology is an independent poor prognostic factor for DFS in patients with stage III colon cancer after adjuvant FOLFOX chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23943026     DOI: 10.1245/s10434-013-3169-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  35 in total

Review 1.  Rate of dissemination and prognosis in early and advanced stage colorectal cancer based on microsatellite instability status: systematic review and meta-analysis.

Authors:  James W T Toh; Kevin Phan; Faizur Reza; Pierre Chapuis; Kevin J Spring
Journal:  Int J Colorectal Dis       Date:  2021-02-18       Impact factor: 2.571

2.  Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma.

Authors:  Kentaro Inamura; Mai Yamauchi; Reiko Nishihara; Sun A Kim; Curtis C Harris; Zhi Rong Qian; Shuji Ogino; Kosuke Mima; Yasutaka Sukawa; Tingting Li; Mika Yasunari; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Charles S Fuchs
Journal:  Ann Surg Oncol       Date:  2014-10-18       Impact factor: 5.344

3.  Prognostic implications of mucinous histology in stage III colon cancer with the receipt of adjuvant chemotherapy.

Authors:  Feng Yu; Luqiao Huang; Feng Shen; Shuang Wu; Jian Chen
Journal:  J Gastrointest Oncol       Date:  2020-10

4.  The Impact of Histologic Subtype on Receipt of Adjuvant Chemotherapy and Overall Survival in Stage III Colon Cancer: a Retrospective Cohort Analysis.

Authors:  Benjamin D Powers; Seth I Felder; Iman Imanirad; Sophie Dessureault; Sean P Dineen
Journal:  J Gastrointest Cancer       Date:  2021-06

Review 5.  Advances in the care of patients with mucinous colorectal cancer.

Authors:  Niek Hugen; Gina Brown; Robert Glynne-Jones; Johannes H W de Wilt; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2015-09-01       Impact factor: 66.675

6.  Mismatch repair deficiency as a prognostic factor in mucinous colorectal cancer.

Authors:  Juliana Andrici; Mahtab Farzin; Loretta Sioson; Adele Clarkson; Nicole Watson; Christopher W Toon; Anthony J Gill
Journal:  Mod Pathol       Date:  2016-01-15       Impact factor: 7.842

7.  Role of Chronic Inflammatory Ratios in Predicting Recurrence of Resected Patients with Stage I-III Mucinous Colorectal Adenocarcinoma.

Authors:  Yu-Cui Liao; Hou-Qun Ying; Ying Huang; Yan-Ran Luo; Cui-Fen Xiong; Ruo-Wei Nie; Xiao-Juan Li; Xue-Xin Cheng
Journal:  Cancer Manag Res       Date:  2021-04-20       Impact factor: 3.989

8.  Survival after curative resection for stage I colorectal mucinous adenocarcinoma.

Authors:  Liang Huang; Shuangling Luo; Sicong Lai; Zhanzhen Liu; Huanxin Hu; Mian Chen; Liang Kang
Journal:  BMC Gastroenterol       Date:  2022-04-18       Impact factor: 3.067

9.  Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation.

Authors:  David S Williams; Dmitri Mouradov; Marsali R Newman; Elham Amini; David K Nickless; Catherine G Fang; Michelle Palmieri; Anuratha Sakthianandeswaren; Shan Li; Robyn L Ward; Nicholas J Hawkins; Iain Skinner; Ian Jones; Peter Gibbs; Oliver M Sieber
Journal:  Mod Pathol       Date:  2020-02-11       Impact factor: 7.842

10.  Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.

Authors:  Gerardo Rosati; Fabio Galli; Maurizio Cantore; Francesca Bergamo; Maria Banzi; Maria Giulia Zampino; Rodolfo Mattioli; Giovanni Gerardo Cardellino; Monica Ronzoni; Maria Di Bartolomeo; Stefano Tamberi; Paolo Marchetti; Lorenza Rimassa; Domenico Corsi; Anna Maria Bochicchio; Fabrizio Artioli; Roberto Labianca; Francesca Galli; Eliana Rulli; Domenico Bilancia; Giacomo Bregni
Journal:  Oncologist       Date:  2020-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.